Core Viewpoint - The stock price of Anglikon has experienced a significant deviation, with a cumulative increase of over 20% over two consecutive trading days, triggering an abnormal trading fluctuation notice [1] Company Information - Anglikon confirmed that there is no need to correct or supplement previously disclosed information, and there are no major undisclosed matters regarding the company's operations [1] - The company is currently conducting a Phase I clinical trial for its innovative drug project ALK-N001, which involves long research cycles, substantial investment, and uncertain outcomes [1]

人民财讯8月3日电，昂利康（002940）8月3日晚发布股票交易异常波动公告，公司关注到近期市场对创 新药业务关注度较高。公司目前在研的创新药项目仅有一个，系ALK-N001项目，该项目于2025年4月 获得药物临床试验批准通知书，截至公告披露日，该项目尚处于I期临床试验阶段。另外，公司关注到 近期有投资者关心公司ALK-N002项目，该项目系公司于2025年年初计划新引入的创新药管线项目，已 列入年度募集资金投资项目实施内容的调整计划中，截至公告披露日，该项目有多个候选药物在筛选和 商榷中，尚未确定具体管线，由于候选药物的相关适应症涉及商业秘密，公司将依据项目进展情况严格 按照相关规定及时履行信息披露义务。 ...

Core Viewpoint - The stock of Anglikang (002940.SZ) experienced significant price fluctuations, with a cumulative increase of over 20% in two consecutive trading days, prompting an investigation by the company's board of directors [1] Group 1: Stock Trading Anomalies - The stock price deviation occurred on July 31 and August 1, 2025, indicating abnormal trading activity [1] - The company confirmed that there were no undisclosed significant matters that could have influenced the stock price [1] - The operational status of the company remains normal, with no significant changes in its main business or external operating environment [1] Group 2: Innovation Drug Projects - The company is currently focused on its innovative drug project ALK-N001, which received clinical trial approval in April 2025 and is in Phase I trials [2] - There is investor interest in the ALK-N002 project, which is part of the company's adjusted fundraising investment plan for 2025, with multiple candidate drugs under consideration [2] - The company emphasizes the long cycle, high investment, and uncertainty associated with innovative drug development, urging investors to be aware of investment risks [2]

Group 1 - The stock of Zhejiang Anglikang Pharmaceutical Co., Ltd. (stock code: 002940) experienced an abnormal price fluctuation, with a cumulative closing price deviation exceeding 20% over two consecutive trading days (July 31, 2025, and August 1, 2025) [1] - The company's board of directors conducted an investigation and confirmed that there were no undisclosed significant matters affecting the stock price, and the company's operational status remains normal [1][2] - The company has one innovative drug project, ALK-N001, which is currently in Phase I clinical trials, and is aware of investor interest in another project, ALK-N002, which is still in the candidate selection phase [2] Group 2 - The innovative drug development and investment are characterized by long cycles, high investment, and significant uncertainty, which investors should be aware of [2]

证券代码：002940 证券简称：昂利康 公告编号：2025-058 浙江昂利康制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 4、经核查，公司及控股股东、实际控制人不存在关于本公司的应披露而未 披露的重大事项，也不存在处于筹划阶段的重大事项； 5、经核查，公司控股股东和实际控制人在股票交易异常波动期间不存在买 卖公司股票的行为； 6、公司关注到近期市场对创新药业务关注度较高。公司目前在研的创新药 项目仅有一个，系 ALK-N001 项目，该项目于 2025 年 4 月获得药物临床试验批 一、股票交易异常波动的情况介绍 浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）股票（证 券代码：002940，证券简称：昂利康）连续 2 个交易日（2025 年 7 月 31 日、2025 年 8 月 1 日）收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规 则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动情况，公司董事会对有关事项进行了核查，有关 情况说明如 ...

Core Viewpoint - The company has approved a share repurchase plan to buy back a portion of its publicly issued shares using its own funds and a special loan, with a total repurchase amount between RMB 50 million and RMB 70 million, and a maximum price of RMB 21.07 per share [1] Group 1: Share Repurchase Plan - The company plans to use its own funds and a special loan to repurchase shares, with a total amount not less than RMB 50 million and not exceeding RMB 70 million [1] - The repurchase price will not exceed RMB 21.07 per share, and the actual number of shares repurchased will depend on the execution [1] - The implementation period for the repurchase is set for up to 12 months from the board's approval date [1] Group 2: Progress of Repurchase - As of July 31, 2025, the company has repurchased a total of 3,599,700 shares, accounting for approximately 1.78% of the total share capital [2] - The highest transaction price during the repurchase was RMB 17.00 per share, while the lowest was RMB 12.17 per share, with a total transaction amount of RMB 50,001,275.28 (excluding transaction fees) [2] Group 3: Compliance and Regulations - The company has adhered to the regulations set forth by the Shenzhen Stock Exchange regarding share repurchase, including not repurchasing during significant events that could impact share prices [3] - The repurchase transactions comply with the requirements that the entrusted price must not exceed the daily trading limit and must not occur during specific trading periods [3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [3]

Market Overview - On the first trading day of August, the A-share market experienced overall weakness, with major sectors such as oil and petrochemicals, semiconductors, and non-bank financials adjusting, leading to declines in the three major stock indices [2] - The Shanghai Composite Index closed at 3559.95 points, down 0.37%; the Shenzhen Component Index closed at 10991.32 points, down 0.17%; and the ChiNext Index closed at 2322.63 points, down 0.24% [2] - The total trading volume in the Shanghai and Shenzhen markets was 15,983 billion yuan, a decrease of over 3,300 billion yuan compared to the previous trading day [2] Solar Equipment Sector - The solar equipment sector showed strong performance, with the Shenwan Solar Equipment Index closing up 2.60%, leading all secondary industries [3] - Companies such as Jiejia Weichuang and Shuangliang Energy reached the daily limit [3] - The Ministry of Industry and Information Technology recently issued a special energy-saving inspection task list for the polysilicon industry for 2025, requiring local authorities to implement and report results by September 30 [3] - According to China International Capital Corporation (CICC), this move is aimed at optimizing the supply side of the industry and may lead to the exit of backward production capacity, particularly affecting the upstream polysilicon segment [3] Express Delivery Sector - The express delivery sector also performed actively, with the Shenwan Logistics Index rising by 1.53% [3] - Companies such as YTO Express, Shentong Express, and Yunda Holdings saw increases of over 6%, while other stocks like Debang Logistics also followed suit [3] - On July 29, the State Post Bureau held a meeting with express delivery companies to address issues related to "involution" competition and promote high-quality industry development [4] Innovative Drug Sector - The innovative drug sector remained active, with stocks like Weikang Pharmaceutical hitting a 20% daily limit, and companies such as Anglikang and Guizhou Bailin recording consecutive gains [5] - Recent announcements from companies like Haizike and Huahai Pharmaceutical regarding new drug applications have contributed to the sector's momentum [5] - According to Dongfang Securities, the global innovative drug field is shifting from "Made in China" to "Created in China," with domestic pharmaceutical companies enhancing their international competitiveness [5] Dividend and Resource Sectors - Looking ahead to August, the strategy team at Industrial Securities suggests focusing on dividend sectors and resource industries for investment opportunities [6] - Historical data indicates that the first half of August typically sees fewer companies disclosing semi-annual results, leading to a higher success rate for small-cap stocks [6] - As the month progresses and companies begin to report earnings, larger-cap stocks with earnings certainty are expected to gain more attention, particularly in resource sectors like coal and petrochemicals [6]

证券日报网讯8月1日晚间，昂利康（002940）发布公告称，截至2025年7月31日，公司通过回购专用证 券账户以集中竞价交易方式累计回购股份数量为3，599，700股，约占公司总股本的1.78%。 ...

Core Viewpoint - The recent approval of new drug formulations by Zhejiang Anglikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Anglikang") highlights the company's strong drug development capabilities and strategic shift towards innovative drugs, which is expected to enhance its market position and revenue growth. Group 1: Recent Approvals and Product Pipeline - Anglikang received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets, classified as a Class 3 chemical drug, which is intended for adult patients with type 2 diabetes [1] - In addition to the Sitagliptin Metformin, Anglikang has also received approvals for Amlodipine Besylate Tablets (5mg, 10mg) and Methocarbamol Injection, expanding its product offerings in hypertension and acute muscle pain treatments [1] - The recent approvals indicate Anglikang's effective execution in drug development, clinical trials, and registration processes, showcasing its robust research capabilities [1] Group 2: Strategic Transformation and Innovation - Anglikang is transitioning from a focus on generic drugs to a strategy that emphasizes both generics and innovative drugs, achieving significant breakthroughs in the innovative drug sector [2] - The company has developed ALK-N001, a globally innovative small molecule conjugate drug for tumor microenvironment activation, which has received clinical trial approval, potentially offering new treatment options for advanced solid tumor patients [2] - Successful commercialization of innovative drugs could significantly enhance Anglikang's economic benefits and core competitiveness, positioning the company favorably in future market competition [2] Group 3: Exploration of New Markets - Anglikang is actively exploring the pet medicine sector, with multiple products expected to receive approval by the end of 2024 and several new veterinary drugs entering clinical trials [2] - The exploration of innovative and pet medicine sectors is anticipated to optimize Anglikang's existing product structure and attract more investment opportunities, supporting stable growth in both domestic and international markets [2]

Core Insights - On August 1, institutional investors showed significant activity in the stock market, with a total of 38 stocks being involved, of which 18 experienced net buying and 20 faced net selling [1][2]. Group 1: Institutional Net Buying - The top three stocks with the highest net buying by institutions were Anglikang, Tianfu Culture Tourism, and Shen Sanda A, with net buying amounts of 186 million, 152 million, and 104 million respectively [1][2]. - Other notable stocks with institutional net buying included Asia-Pacific Pharmaceutical (10,215.46 million), New Henghui (7,762.80 million), and Huason Pharmaceutical (4,635.90 million) [2]. Group 2: Institutional Net Selling - The top three stocks with the highest net selling by institutions were Beifang Changlong, Kechuan Technology, and Jinling Sports, with net selling amounts of 108 million, 72.88 million, and 35.16 million respectively [1][3]. - Additional stocks that faced significant net selling included Shunlian Biotech (1,968.76 million), Ruikeda (2,306.42 million), and Jinyang Sports (3,515.56 million) [3].